An imaging endpoint and a clinical-event endpoint require separate conclusions. This NAD+ trial provides a recent example of that distinction. NAD+ is a coenzyme, not a peptide. Primary study
Trial findings
The single-center trial randomized 180 adults with ischemic cardiomyopathy to a short NAD+ infusion course or placebo alongside guideline-directed care. The report found a greater improvement in left-ventricular ejection fraction at one month. Six-month composite events and heart-failure hospitalization showed favorable numerical trends that were not statistically significant. Registration: ChiCTR2200059169. Primary report
Our appraisal: preserve the endpoint hierarchy
A positive primary physiological endpoint does not automatically make every secondary endpoint positive. Each estimate needs its own uncertainty, analysis population, and follow-up window. In particular, a hospitalization trend should not become a demonstrated reduction in hospitalization.
The change from baseline and the final measured value are different statistics. Both may be reported, but they should not be conflated. A clear account identifies which comparison was prespecified and how baseline values were handled.
An add-on trial also does not test replacement of established heart-failure care. The background treatment is part of the clinical context. The same result cannot automatically be transferred to a wellness infusion, another exposure schedule, or people without this cardiac condition.
The full report contains numerical presentation details that merit reconciliation before quantitative reuse, including baseline percentage denominators. Such issues should be checked against tables, participant flow, and any corrections rather than silently repaired.
This study supports further investigation of a specific adjunctive intervention. It does not establish a survival benefit, validate broad anti-aging claims, or settle long-term infusion safety. Multicenter confirmation with patient-important outcomes would materially strengthen the evidence.
Frequently asked questions
Is NAD+ a peptide?
No.
Was established cardiac care continued?
Yes.
Did the ejection-fraction comparison favor NAD+?
Yes.
Were the clinical-event trends statistically confirmed?
No.
Are final values and changes from baseline identical statistics?
No.
Does this validate wellness or anti-aging infusions?
No.
What evidence would strengthen clinical interpretation?
Replicated, well-powered comparisons of patient-important outcomes and harms.